Chemotherapy-induced cardiotoxicity from molecular bases to clinical perspective. ISSN Nowadays cancer represents an epidemic that can be considered a public health problem. That is why pharmacological development has emerged for improving survival and remission rates. Nevertheless, this has been obscured by the toxicity of these therapies. Cardiotoxicity is a known adverse event of oncologic therapy that many times limits a correct regimen of administration thus lowering efficacy; therefore, understanding pathophysiological and molecular bases is essential in order to determine preventive and therapeutical measures that can allow a reduction in the incidence of toxicity, without interfering in the efficacy of the cancer therapy.
|Published (Last):||23 November 2010|
|PDF File Size:||3.79 Mb|
|ePub File Size:||19.61 Mb|
|Price:||Free* [*Free Regsitration Required]|
Background: Anthracyclines are effective drugs in pediatrics cancer treatment. However, anthracycline-induced cardiotoxicity AIC is a serious adverse drug reaction that affects the survival in patients treated for childhood cancer.
After last chemotherapy dose, the patient was admitted with systemic inflammatory response, asthenia and adinamia. Patient died 2 days after diagnosed with dilated cardiomyopathy secondary to anthracyclines.
After the last cycle, the patient developed several infectious foci. Patient died 13 days after diagnosis of dilated cardiomyopathy by anthracyclines. Conclusion: AIC is a problem in pediatric patients receiving anthracyclines, monitoring is essential to detect the onset of cardiac damage to provide an intervention to prevent heart failure progress.
Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text. Send email Cancel. Add to Collections Create a new collection Add to an existing collection.
Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again. Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items.
Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel. Cite Favorites. Abstract in English , Spanish. Similar articles Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in patients. Jensen BV, et al. Ann Oncol.
Anthracycline-induced cardiomyopathy in a dog treated with epirubicin. Lee YR, et al. Can Vet J. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Seymour L, et al. Cancer Prev Control. PMID: Nelson-Veniard M, et al. Bull Cancer. Epub Apr PMID: Review. Vasyuk YA, et al. Show more similar articles See all similar articles. PLoS One. Publication types Case Reports Actions. MeSH terms Adolescent Actions.
Cardiotoxicity Actions. Child Actions. Fatal Outcome Actions. Female Actions. Humans Actions. Substances Antibiotics, Antineoplastic Actions. Epirubicin Actions. Copy Download.
2013, Número 2
Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologist. E-mail address: jsalazar bellvitgehospital. Received April 25, Accepted August 20, Anthracyclines are cytostatic antibiotics discovered almost half a century ago exerting their action through inhibition of topoisomerase II.
[Anthracycline-induced Cardiotoxicity: Report of Fatal Cases]
Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies. J Am Coll Cardiol ; 56 20 : Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci ; 1 : Gupta R, Maitland ML. Curr Hypertens Rep ; 13 6 : Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.
ISSN X. Materials and methods: The study had a non-experimental, descriptive and retrospective design. The study population consisted of patients treated at the Cardiology Service due to cardiovascular discomfort during chemotherapy. Results : Nine hundred eighty-five evaluations were performed because of cardiac symptoms in patients undergoing antineoplastic treatment.